Abstract| Volume 18, ISSUE 6, SUPPLEMENT , S17, June 2016

A Placebo-Controlled, Randomized Trial of Mesenchymal Stromal Cells Combined with One-Way Endobronchial Valve Therapy in Severe COPD

      Rationale: Chronic obstructive pulmonary disease (COPD) is a devastating disease affecting millions worldwide, and therapeutic options are limited. One-way endobronchial valves (EBV) have been used in emphysema patients with dynamic hyperinflation, heterogeneity, and collateral ventilation to reduce lobar volume and improve lung function. However, EBV may increase rates of respiratory infection, COPD exacerbation, and hemoptysis. Mesenchymal stromal cells (MSCs) secrete antibacterial peptides, promote the anti-inflammatory M2 phenotype, and increase phagocytic activity. Thus, we hypothesized that administration of MSCs prior to EBV placement would improve lung function and quality of life in patients with severe heterogeneous COPD.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect